LifeMD, Inc. (NASDAQ:LFMD) CMO Jessica Friedeman Sells 30,000 Shares of Stock

LifeMD, Inc. (NASDAQ:LFMD) CMO Jessica Friedeman sold 30,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.66, for a total value of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares of the company’s stock, valued at $962,200. This represents a 15.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

LifeMD Stock Performance

LFMD opened at $5.71 on Tuesday. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88. The firm has a market capitalization of $254.57 million, a PE ratio of -8.92 and a beta of 1.50. The business’s 50-day simple moving average is $5.68 and its 200 day simple moving average is $5.39.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The business had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. On average, research analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on LFMD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research report on Tuesday, March 11th. B. Riley raised LifeMD to a “strong-buy” rating in a research report on Tuesday, March 11th. Lake Street Capital initiated coverage on LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. KeyCorp dropped their target price on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright upped their target price on LifeMD from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.43.

Institutional Trading of LifeMD

Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp raised its stake in LifeMD by 20.0% in the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after buying an additional 192,861 shares during the period. Royce & Associates LP raised its stake in LifeMD by 23.9% in the fourth quarter. Royce & Associates LP now owns 1,115,991 shares of the company’s stock valued at $5,524,000 after buying an additional 214,950 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in LifeMD by 21.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company’s stock valued at $4,610,000 after buying an additional 165,378 shares during the period. Millennium Management LLC raised its stake in LifeMD by 17.1% in the fourth quarter. Millennium Management LLC now owns 885,987 shares of the company’s stock valued at $4,386,000 after buying an additional 129,327 shares during the period. Finally, Geode Capital Management LLC raised its stake in LifeMD by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock valued at $4,071,000 after buying an additional 2,984 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.